Fructose induces prothrombotic phenotype in human endothelial cells: A new role for “added sugar” in cardio-metabolic risk

Journal of Thrombosis and Thrombolysis

Volumn 40, Issue 4, 2015, Pages 444-451

  Cirillo, Plinio ^a   Pellegrino, Grazia ^a   Conte, Stefano ^b   Maresca, Fabio ^a   Pacifico, Francesco ^a   Leonardi, Antonio ^a   Trimarco, Bruno ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Atherothrombosis; Fructose; Tissue factor

Indexed keywords

FRUCTOSE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MONOSACCHARIDE; PROCOAGULANT; SUPEROXIDE DISMUTASE; THROMBOPLASTIN; SWEETENING AGENT;

ARTICLE; ATHEROSCLEROSIS; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CELL STIMULATION; CONCENTRATION (PARAMETERS); ENZYME REPRESSION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; UMBILICAL VEIN ENDOTHELIAL CELL; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; METABOLISM; PATHOLOGY; THROMBOSIS;

ATHEROSCLEROSIS; FRUCTOSE; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NF-KAPPA B; SWEETENING AGENTS; THROMBOPLASTIN; THROMBOSIS; TRANSCRIPTION, GENETIC;

EID: 84942503439     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1243-1     Document Type: Article

References (50)

1. Johnson RK, Appel LJ, Brands M, et al; American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism and the Council on Epidemiology and Prevention (2009) Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation 120:1011–1020
2. Hubert HB, Feinleib M, McNamara PM et al (1983) Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67:968–977
3. Sowers JR (2003) Obesity as a cardiovascular risk factor. Am J Med 115:37–41
4. Tappy L, Le KA (2010) Metabolic effects of fructose and the world wide increase in obesity. Physiol Rev 90:23–46
5. Khitan Z, Kim DH (2013) Fructose: a key factor in the development of metabolic syndrome and hypertension. J Nutr Metab 2013:682673
6. Cozma AI, Sievenpiper JL, de Souza RJ et al (2012) Effects of fructose on glycemic control in diabetes: a systematic review and meta-analysis of controlled feeding trials. Diabetes Care 35:1611–1620
7. Bray GA (2012) Fructose and risk of cardiometabolic disease. Curr Atheroscler Rep 14:570–578
8. Beck-Nielsen H, Pedersen O, Lindskoc HO (1980) Impaired cellular insulin binding and insulin sensitivity induced by high-fructose feeding in normal subjects. Am J Clin Nutr 33:273–278
9. Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115–126
10. Price DT, Loscalzo J (1999) Cellular adhesion molecules and atherogenesis. Am J Med 107:85–97
11. Simionescu M (2007) Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol 27(2):266–274
12. Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874
13. O’Brien KD, McDonald TO, Chait A et al (1996) Neovascular expression of E-selectin, intercellular adhesion molecule-1 and vascular adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 93:672–682
14. Glushakova O, Kosugi T, Roncal C et al (2008) Fructose induces the inflammatory molecule ICAM-1 in endothelial cells. J Am Soc Nephrol 19:1712–1720
15. Toschi V, Gallo R, Lettino M et al (1997) Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95(3):594–599
16. Ragni M, Cirillo P, Pascucci I et al (1996) A monoclonal antibody against tissue factor shortens tissue-plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 93:1913–1920
17. Bierhaus A, Chen J, Liliensiek B et al (2000) LPS and cytokine activated endothelium. Semin Thromb Hemost 26:571–587
18. Golino P, Ragni M, Cirillo P et al (1996) Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med 2:35–40
19. Cirillo P, Golino P, Calabro P et al (2005) C-Reactive Protein induces Tissue Factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 68(1):47–55
20. Cirillo P, Angri V, De Rosa S et al (2010) Pro athero-thrombotic effects of leptin in human coronary endothelial cells. Thromb Haemost 103(5):1065–1075
21. Cirillo P, Ziviello F, Pellegrino G et al (2015) The adipokine apelin-13 induces expression of prothrombotic tissue factor. Thromb Haemost 113(2):363–372
22. Rajwani A, Cubbon RM, Wheatcroft SB (2012) Cell specific insulin resistance: implications for atherosclerosis. Diabetes Metab Res Rev 28:627–634
23. Jindal A, Garcia-Touza M, Jindal N (2013) Jindal N et al Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives. Endocrinol Metab Clin N Am 42:789–808
24. Tan HW, Xing SS, Bi XP, Li L et al (2008) Felodipine attenuates vascular inflammation in a fructose-induced rat model of metabolic syndrome via the inhibition of NF-kB activation. Acta Pharmacol Sin 29:1051–1059
25. Eckel RH, Grundy SM, Zimmet PS (2005) The metabolic syndrome. Lancet 365:1415–1428
26. Berg AH, Scherer PE (2005) Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96:939–949
27. 2 imbalance in insulin resistant rat aorta. Diabetes 48:2437–2445
28. Gami AS, Witt BJ, Howard DE et al (2007) Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49:403–414
29. Cox CL, Stanhope KL, Schwars JM et al (2011) Circulating concentrations of monocyte chemoattractant protein-1, plasminogen activator inhibitor-1 and soluble leukocyte adhesion molecule-1 in overweight/obese men and women consuming fructose- or glucose-sweetened beverages for 10 weeks. J Clin Endocrinol Metab 96:2034–2038
30. Dandona P, Aljada A, Chaudhuri A et al (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111:1448–1454
31. Silbernagel G, Machann J, Haring HU et al (2014) Plasminogen activator inhibitor-1, monocyte chemoattractant protein-1, e-selectin and C-reactive protein levels in response to 4-week very high-fructose or -glucose diet. Eur J Clin Nutr 68:97–100
32. Van De Craen B, Declerck PJ, Gils A (2012) The biochemistry, physiology and pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res 130(4):576–585
33. Meigs JB, Mittleman MA, Nathan DM et al (2000) Hyperinsulinemia, hyperglycemia and impaired hemostasis: the Framingham Offspring Study. JAMA 283:221–228
34. Pandolfi A, Cetrullo D, Polishick R et al (2001) Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thrombo Vasc Biol 21:1378–1382
35. Van der Wouwer M, Collen D, Conway EM et al (2004) Thrombomodulin-protein C E-EPCR system. Integrated to regulate coagulation and inflammation. Arter Thromb Vasc Biol 24:1374–1383
36. Wang HJ, Huang HC, Chuang YC et al (2012) Modulation of tissue factor and thrombomodulin expression in human aortic endothelial cells incubated with high glucose. Acta Diabetol 49:125–130
37. Conway EM, Liu L, Nowakosky B et al (1994) Heat shock of vascular endothelial cells induces and up-regulatory transcriptional response of the thrombomodulin gene that is delayed in onset and does not attenuate. J Biol Chem 269:22804–22810
38. Barnes PJ, Karin M (1997) Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory disease. N Engl J Med 336:1066–1071
39. Flohe L, Brigelius-Flohe R, Saliou C et al (1997) Redox regulation of NF-kappa B activation. Free Radic Biol Med 22:1115–1126
40. Oeth P, Parry GC, Mackman N (1997) Regulation of the tissue factor gene in human monocytic cells. Arterioscler Thromb Vasc Biol 17(2):365–374
41. Ritchie ME (1998) Nuclear Factor-κB is selectively and markedly activated in humans with unstable angina pectoris. Circulation 98:1707–1713
42. Wilson SH, Best PJ, Edwards WD et al (2002) Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis 160:147–153
43. Carmeliet P, Mackman N, Moons L et al (1996) Role of tissue factor in embryonic blood vessels development. Nature 383:73–75
44. Bromberg ME, Sundaraman R, Homer RJ et al (1995) Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 92:8205–8209
45. Randolph GJ, Luther T, Albrecht A et al (1998) Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro. Blood 2:4167–4177
46. Riewald M, Ruf W (2001) Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 98:7742–7747
47. Lima LG, Monteiro RQ (2013) Activation of blood coagulation in cancer: implication for tumor progression. Biosci Rep 33:e00064
48. Cirillo P, Calì G, Golino P et al (2004) Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation 109:2911–2916
49. van den Berg YW, Osanto S, Reitsma PH et al (2012) The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 119:924–932
50. Das UN (2015) Sucrose, fructose, glucose and their link to metabolic syndrome and cancer. Nutrition 31:249–257